Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Clinical trial NCT02639247 · COMPLETED
Trial details
- NCT number
- NCT02639247
- Sponsor
- Gilead Sciences
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-23
- Primary completion
- 2016-10-05
- Enrollment
- 333
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.